Kissei Pharmaceutical Co.

Kissei Pharmaceutical Co.

Kissei Pharmaceutical Co. is a publicly traded Japanese pharmaceutical firm headquartered in Matsumoto, Nagano. The company's origins go back decades, though its exact founding year is not disclosed on its corporate website. It operates as a research-driven organization focused on developing and commercializing prescription medicines. The company's pipeline spans acute myeloid leukemia (with the drug olutasidenib, for which it filed a manufacturing and marketing approval application in Japan in May 2026), ANCA-associated vasculitis (Tabneos capsules), and various urological and gynecological therapies. Kissei also runs a healthcare division selling consumer health foods in Japan. Its product portfolio targets multiple therapeutic areas, but oncology and autoimmune disorders are the most prominent focuses. Geographic operations are centered on Japan, with additional offices in Los Angeles, Menlo Park, and Sao Paulo. Kissei employs around 1,100 people per its corporate materials (per Kissei website). May 2026 saw the company issue a safety alert regarding serious liver dysfunction in patients using Tabneos, alongside its filing for olutasidenib approval. The firm also maintains a sustainability program with a stated focus on nurturing the next generation (per Kissei website). A structural differentiator is that Kissei operates as a conventional publicly listed pharma, not a family office or asset manager. Its capital allocation is directed entirely into R&D, regulatory approvals, and product commercialization, with no disclosed investment portfolio or external manager relationships.